Literature DB >> 27442317

An Intractable Case of Prototheca Keratitis and Chronic Endophthalmitis in Stevens-Johnson Syndrome With Boston Type 1 Keratoprosthesis.

Jacqueline Ng1, Don Minckler, Thomas J Walsh, Marjan Farid.   

Abstract

PURPOSE: To report a case of recalcitrant Prototheca spp. keratitis and endophthalmitis in a patient with Stevens-Johnson syndrome (SJS) and Boston type 1 keratoprosthesis (B1 KPro).
METHODS: Case report.
RESULTS: A 67-year-old female with a history of SJS with chronic severe ocular surface disease in her monocular left eye underwent placement of a B1 KPro. Her course was subsequently complicated by persistent Prototheca spp. keratitis and endophthalmitis requiring ongoing treatment with triazole and polyene antifungal agents and multiple surgical revisions of her keratoprosthesis.
CONCLUSIONS: Protothecosis is an algal infection that is rarely pathologic in humans, but when present can be difficult to manage. We present the second known case of persistent chronic Prototheca spp. keratitis and endophthalmitis in a patient with long-standing SJS and B1 KPro.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27442317     DOI: 10.1097/ICO.0000000000000949

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  3 in total

1.  Long Term Follow-Up of Prototheca keratitis: A Case Report.

Authors:  Kazumi Minato; Munemitsu Yoshikawa; Hideo Nakanishi; Kaori Hasegawa
Journal:  Int Med Case Rep J       Date:  2020-10-09

Review 2.  Practical Guidance for Clinical Microbiology Laboratories: Diagnosis of Ocular Infections.

Authors:  Sixto M Leal; Kyle G Rodino; W Craig Fowler; Peter H Gilligan
Journal:  Clin Microbiol Rev       Date:  2021-06-02       Impact factor: 50.129

3.  Unusual ulcerative keratitis caused by Prototheca wickerhamii in a diabetic patient.

Authors:  Niveditha Narayanan; D Vaidehi; L Dhanurekha; K Lily Therese; Rama Rajagopal; Radhika Natarajan; Meena Lakshmipathy
Journal:  Indian J Ophthalmol       Date:  2018-02       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.